MedTrace Logo

A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer Pain

NCT03176199 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-03-18

No results posted yet for this study

Summary

This study is to evaluate the efficacy and safety of a titration method by selects 10 mg control-released (CR) oxycodone tablet as background drug in combined with immediate-released (IR) oxycodone, compared to conventional titration method with immediate-released (IR) oxycodone in patients with moderate to severe cancer pain in Taiwan.

Conditions

Interventions

DRUG

Oxycodone

Every 12 hours for control-released oxycodone (OxyContin®)

DRUG

Oxycodone

Every 6 hours for immediate-released oxycodone (OxyNorm®)

Sponsors & Collaborators

  • Taiwan Mundipharma Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Chih-Jen Hung, MSc · Taichung Veterans General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-01
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03176199 on ClinicalTrials.gov